This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Merck & Co., Inc.

Drug Names(s): Cefoxitin

Description: Mefoxin is a cephamycin antibiotic, a group of beta lactams that is commonly grouped with second generation cephalosporins due to their similar properties. Compared to first generation cephalosporins such as Keflex, second generation cephalosporins exhibit better Gram-(-) activity and somewhat weaker Gram-(+) activity. They are more stable to Gram-(-) beta lactamases. They exhibit good activity against many enteric Gram-(-) rods, Haemophilus influenzae, and Neisseria gonorrheae; moderate activity against streptococci and staphylococci; and poor activity against enterococci, methacillin resistant Staphylococcus aureus and Psuedomonas. In addition to these activities, the cefamycins exhibit activity against anaerobes.

Deal Structure: Mefoxin is a registered trademark of Bioniche Teoranta (Bioniche Pharma's operating subsidiary) and is marketed by Merck & Co.

In December 2006, RoundTable Healthcare Partners completed its purchase of Bioniche Life Sciences' 10% ownership stake in Bioniche Pharma, their injectable generic and specialty pharmaceuticals unit.

In July 2010, Mylan announced plans to acquire Bioniche Pharma for $550 million in cash from RoundTable Healthcare. Mylan is not assuming any of Bioniche Pharma's outstanding debt or acquiring the company's cash as part of the transaction. Mylan expects to finance this transaction using a combination of cash on hand and available borrowings. In September 2010, Mylan announced it had completed the acquisition of Bioniche Pharma.

Teva and Mylan
In April 2015, Teva proposed to acquire all of the outstanding shares of Mylan in a transaction valued at $82.00 per Mylan share, with the consideration to be comprised of approximately 50 percent...See full deal structure in Biomedtracker

Partners: Mylan Inc.

Mefoxin News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug